相关实验视频

Updated: May 25, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

克拉德里宾片对多发性硬化症中区域灰质缩的数据驱动模式的治疗效应

Mar Barrantes-Cepas¹, Samantha Noteboom¹, Elisa Colato¹

¹MS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, Amsterdam, The Netherlands.

Multiple sclerosis (Houndmills, Basingstoke, England)

|February 26, 2025

概括

克拉迪宾片 (CladT) 通过减少灰质缩,特别是在深灰质和质中,减缓复发性复发性多发性硬化症 (RRMS) 中的神经退行. 这项MRI研究强调了评估治疗疗效的区域措施.

科学领域:

神经成像是一种神经成像.
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

复发性缓解性多发性硬化症 (RRMS) 的特征是神经退行.
克拉迪片 (CladT) 已显示出降低RRMS的全球灰质 (GM) 缩的潜力.
克拉德T对区域转基因缩模式的影响在很大程度上是未知的.

研究的目的:

调查克拉迪宾片 (CladT) 与安慰剂对RRMS患者灰色物质 (GM) 缩的磁共振成像 (MRI) 衍生模式的比较影响.
用先进的MRI技术分析区域GM体积变化和缩模式.

主要方法:

利用了来自CLARITY研究的MRI和临床数据 (n=393名RRMS患者).
在96周内使用SynthSeg和基于源的形态测量评估了GM缩模式.
采用混合效应模型来分析群体差异和与残疾的关联 (EDSS).

主要成果:

与CladT组相比,安慰剂组在深层GM,丘脑和脑干-丘脑区域呈现出更大的缩.
在伪缩期内没有观察到显著的区域缩差异.
扩展残疾状态量表 (EDSS) 的得分与在24-96周之间减少的深层GM和胸膜体积相关.

结论:

克拉迪布林片 (CladT) 在缓慢RRMS的神经退行变化方面显示出临床相关的效果.
观察到最强的神经保护作用是在深层的GM,丘脑和脑干中.
区域MRI措施对于准确评估CladT在RRMS中的治疗效果至关重要.

关键词:

缩性缩症缩性缩症身体残疾就是残疾.改变疾病的疗法.多发性硬化症多发性硬化症治疗对治疗的反应反应.

更多相关视频

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

$MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor$ 05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...